From: Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis
Characteristic | N | % |
---|---|---|
chromosome 10 | ||
Gain | 3 | 23.1 |
Loss | 6 | 46.2 |
Structural anomaly | 4 | 30.8 |
Sex | ||
Male | 6 | 46.2 |
Female | 7 | 53.8 |
MYCN | ||
Amplification | 10 | 76.9 |
Not amplification | 3 | 23.1 |
1p36 | ||
Lost | 8 | 61.5 |
Not lost | 3 | 23.1 |
None | 2 | 15.4 |
LDH (U/L) | ||
≤295 | 0 | 0 |
295–500 | 3 | 23.1 |
500–1500 | 0 | 0 |
>1500 | 10 | 76.9 |
NSE (ng/l) | ||
≤25 | 1 | 7.7 |
25–100 | 0 | 0 |
>100 | 12 | 92.3 |
VMA (mg/24 h urine) | ||
≤13.6 | 5 | 38.5 |
>13.6 | 7 | 53.8 |
None | 1 | 7.7 |
Primary tumor size | ||
≤5 | 0 | 0 |
5–10 | 4 | 30.8 |
>10 | 8 | 61.5 |
Metastasis site | ||
Bone | 10 | 76.9 |
Bone marrow | 13 | 100 |
Harnpan/Intracalvarium | 9 | 69.2 |
Periorbital | 5 | 38.5 |
Mediastinum | 4 | 30.8 |
Lymph nodes | 11 | 84.6 |
Other visceral organ | 5 | 38.5 |